Clinical characteristics and prognosis of very young patients with breast cancer in the southern of China
10.3321/j.issn:1000-467X.2009.12.014
- VernacularTitle:华南地区年轻乳腺癌患者的临床特征及预后因素分析
- Author:
Yang HUA
1
,
2
;
Wang SI-YU
;
Ou WEI
;
Sun HAI-BO
;
Fang QIN
Author Information
1. 华南肿瘤学国家重点实验室,广东,广州,510060
2. 中山大学肿瘤防治中心胸科,广东,广州,510060
- Keywords:
very young patient;
breast cancer;
clinical characteristic;
prognosis factor
- From:Chinese Journal of Cancer
2009;28(12):1310-1316
- CountryChina
- Language:Chinese
-
Abstract:
Background and Objective: Even though most breast cancers occur in postmenopausal women in western countries,age<35 is one of the prognostic factors.This study was to compare the clinicopathologic characte ristics and prognosis between premenopausal breast cancer patients aged of<35 and≥35 in south China.and to explore the prognostic factors.Methods:A total of 905 consecutive premenopausal patients were evaluated,with first diagnosis of breast cancer referred to surgery at the Sun Yat-sen University Cancer Center from October 2003 to December 2006.The clinicopathologic factors and the survival rates between the very young group (aged of<35 at diagnosis) and the non-young group(aged of≥35 at diagnosis) were retrospectively compared. Results:The overall median follow-up time was 27.77 months.The 3-year disease-free survival rate was significantly lower(78.0%VS.89.1%,P<0.001)and the 3-year survival rate relatively lower(94.3%vs.96.8%,P=0.10)in the very young group than in the non-young group. In addition,the 3-year survival and disease-free survival rates were significantly lower in the very young group with HR (hormone receptor)-positive than in the non-young group(P<0.05).The univariate and multivariate analysis of clinicopathologic characteristics between two groups showed that age<35 at diagnosis,axillary lymph node involvement,presence of vascular invasion, and high expression of Ki67 were risk factors for recurrence. Conclusion: Compared with non-young premenopausal patients,very young breast patients with HR-positive cancer have a worse outcome.
